Nitroxide Labeled Hemoglobin as a Blood Substitute
1 R43 HL53860-01,
A number of biopharmaceutical companies have successfully taken hemoglobin-based oxygen carriers (Hinto phase I clinical trial. However, transfusions have been limited to low dosage levels due to obsvasoconstrictive effects at high dosage levels in pre-clinical animal studies. This proposal deals wfailure to have an oxidant detoxification system similar to the one which is intrinsic to the red blsubstitute. This research plan intends to modify a high- quality HBOC, which is currently in clinicathat stable nitroxide free radicals can be used to perform an oxidant detoxification function. If ththen the groundwork would established for a second generation red blood cell substitute which couldcommercialized.
Small Business Information at Submission:
Principal Investigator:Carleton Hsia
Synzyme Technology, Inc.
1 Technology Drive, E-309 Irvine, CA 92718
Number of Employees: